A bioconjugated MoS2 based nanoplatform with increased binding efficiency to cancer cells.
Anna KálosiMartina LabudováAdriana AnnušováMonika BenkovičováMichal BodíkJozef KollárMário KotlárPeter KasakMatej JergelSilvia PastorekovaPeter ŠiffalovičEva MajkováPublished in: Biomaterials science (2020)
We evaluate the application of surfactant-free liquid-phase exfoliated MoS2 nanosheets as a nanoplatform for a cancer detection and treatment system equipped with an antibody-antigen based recognition element. Employing antigen-antibody binding, we increased the probability of the endocytosis of MoS2 nanosheets into CAIX expressing cells by 30%. The nanosheets are functionalized with a specific antibody M75, which forms an antigen-antibody complex with CAIX. The bioconjugation of MoS2 nanosheets involves biocompatible components with low cytotoxicity, verified in the tested cell lines by fluorescence-based cell viability assay. The cellular internalization is quantified by flow cytometry, while the internalization is confirmed by label-free confocal Raman imaging. Raman measurements show increased lysosomal activity in the proximity of the internalized nanoplatforms.
Keyphrases
- quantum dots
- label free
- reduced graphene oxide
- transition metal
- visible light
- highly efficient
- flow cytometry
- energy transfer
- sensitive detection
- gold nanoparticles
- photodynamic therapy
- room temperature
- induced apoptosis
- drug release
- metal organic framework
- ionic liquid
- high throughput
- papillary thyroid
- squamous cell carcinoma
- raman spectroscopy
- young adults
- cell cycle arrest
- single molecule
- drug delivery
- endoplasmic reticulum stress
- combination therapy
- fluorescence imaging
- pi k akt